| Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ... Journal of Clinical Oncology 38 (1), 1, 2020 | 2221 | 2020 |
| Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018 | 1642 | 2018 |
| Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study JM Sun, L Shen, MA Shah, P Enzinger, A Adenis, T Doi, T Kojima, ... The Lancet 398 (10302), 759-771, 2021 | 845 | 2021 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 754 | 2019 |
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study N Boku, S Yamamoto, H Fukuda, K Shirao, T Doi, A Sawaki, W Koizumi, ... The lancet oncology 10 (11), 1063-1069, 2009 | 738 | 2009 |
| Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ... Journal of Clinical Oncology 38 (35), 4138-4148, 2020 | 728 | 2020 |
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study T Satoh, RH Xu, HC Chung, GP Sun, T Doi, JM Xu, A Tsuji, Y Omuro, J Li, ... J Clin Oncol 32 (19), 2039-2049, 2014 | 695 | 2014 |
| Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study S Modi, H Park, RK Murthy, H Iwata, K Tamura, J Tsurutani, ... Journal of Clinical Oncology 38 (17), 1887, 2020 | 599 | 2020 |
| A multicenter retrospective study of endoscopic resection for early gastric cancer I Oda, D Saito, M Tada, H Iishi, S Tanabe, T Oyama, T Doi, Y Otani, ... Gastric cancer 9, 262-270, 2006 | 560 | 2006 |
| The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies S Kumagai, Y Togashi, T Kamada, E Sugiyama, H Nishinakamura, ... Nature immunology 21 (11), 1346-1358, 2020 | 549 | 2020 |
| Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial K Shitara, T Doi, M Dvorkin, W Mansoor, HT Arkenau, A Prokharau, ... The Lancet Oncology 19 (11), 1437-1448, 2018 | 431 | 2018 |
| Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or … T Doi, K Shitara, Y Naito, A Shimomura, Y Fujiwara, K Yonemori, ... The Lancet Oncology 18 (11), 1512-1522, 2017 | 403 | 2017 |
| Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE‐158 and KEYNOTE‐028 studies SA Piha‐Paul, DY Oh, M Ueno, D Malka, HC Chung, A Nagrial, RK Kelley, ... International journal of cancer 147 (8), 2190-2198, 2020 | 356 | 2020 |
| Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments S Kumagai, S Koyama, K Itahashi, T Tanegashima, Y Lin, Y Togashi, ... Cancer Cell 40 (2), 201-218. e9, 2022 | 336 | 2022 |
| Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study K Tamura, J Tsurutani, S Takahashi, H Iwata, IE Krop, C Redfern, ... The Lancet Oncology 20 (6), 816-826, 2019 | 333 | 2019 |
| Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma T Doi, SA Piha-Paul, SI Jalal, S Saraf, J Lunceford, M Koshiji, J Bennouna Journal of Clinical Oncology 36 (1), 61-67, 2018 | 296 | 2018 |
| Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer T Doi, K Muro, N Boku, Y Yamada, T Nishina, H Takiuchi, Y Komatsu, ... J Clin Oncol 28 (11), 1904-1910, 2010 | 278 | 2010 |
| Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors J Tsurutani, H Iwata, I Krop, PA Jänne, T Doi, S Takahashi, H Park, ... Cancer discovery 10 (5), 688-701, 2020 | 267 | 2020 |
| Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer I Hyodo, T Doi, H Endo, Y Hosokawa, Y Nishikawa, M Tanimizu, K Jinno, ... European journal of cancer 34 (13), 2041-2045, 1998 | 258 | 1998 |
| Phase II study of sunitinib as second-line treatment for advanced gastric cancer YJ Bang, YK Kang, WK Kang, N Boku, HC Chung, JS Chen, T Doi, Y Sun, ... Investigational new drugs 29, 1449-1458, 2011 | 245 | 2011 |
